TransMedics Group, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.

If you purchased TransMedics securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On February 21, 2024, after market hours, U.S. Representative Paul Gosar issued a letter to his Twitter/X feed, accusing TransMedics, among other things, of misappropriating corporate resources.

On this news, TransMedics’ stock price fell $2.18 per share, or 2.5%, to close at $84.81 per share on February 22, 2024.

Follow us on:
Company Name: TransMedics Group, Inc.
Stock Symbol: TMDX
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top